Patents Issued in September 1, 2020
-
Patent number: 10759725Abstract: To provide a method for stably storing tetrafluoropropene filled in a container for e.g. storage or transportation, without occurrence of reaction such as polymerization. A method for storing tetrafluoropropene in a gaseous-liquid state composed of a gas phase and a liquid phase in a closed container, wherein the oxygen concentration (content) in the above gas phase is adjusted to at least 3 vol ppm and less than 3,000 vol ppm at a temperature of 25° C.Type: GrantFiled: September 6, 2019Date of Patent: September 1, 2020Assignee: AGC INC.Inventors: Masato Fukushima, Masaaki Tsuzaki, Maki Shigematsu
-
Patent number: 10759726Abstract: A process for the preparation of ethylene glycol and other C1-C3 hydroxy compounds comprising the steps of hydrogenating a composition comprising C1-C3 oxygenate compounds. In particular the process is suitable for hydrogenating a composition comprising different C1-C3 oxygenate compounds, such as the product from a thermolytic fragmentation of a sugar composition.Type: GrantFiled: January 5, 2017Date of Patent: September 1, 2020Assignee: HALDOR TOPSØE A/SInventors: Martin Spangsberg Holm, Christian Mårup Osmundsen, Esben Taarning, Amanda Birgitte Sølvhøj, Morten Boberg Larsen
-
Patent number: 10759727Abstract: Use of diverse biomass feedstock in a process for the recovery of target C5 and C6 alditols and target glycols via staged hydrogenation and hydrogenolysis processes is disclosed. Particular alditols of interest include, but are not limited to, xylitol and sorbitol. Various embodiments of the present invention synergistically improve overall recovery of target alditols and/or glycols from a mixed C5/C6 sugar stream without needlessly driving total recovery of the individual target alditols and/or glycols. The result is a highly efficient, low complexity process having enhanced production flexibility, reduced waste and greater overall yield than conventional processes directed to alditol or glycol production.Type: GrantFiled: February 17, 2017Date of Patent: September 1, 2020Assignee: INTERCONTINENTAL GREAT BRANDS LLCInventors: Lloyd Allen, Claudio Arato, Terry Brix, Peter Andrew Clarke, Joshua Davies, Bryan Gene, Mark Kirby, Quak Foo Lee, William McKean, Ankit Munjapara, Clive Richard Norton, Stuart A. Stein, Greg Stock, David Sugden
-
Patent number: 10759728Abstract: The invention relates to an improved process and system for the synthesis of dimethyl ether (DME) from a feedstock comprising H2 and COx, wherein x=1-2. The process according to the invention comprises (a) subjecting the gaseous mixture comprising synthesis gas originating from step (c) to DME synthesis by contacting it with a catalyst capable of converting synthesis gas to DME to obtain a gaseous mixture comprising DME; (b) subjecting a gaseous mixture comprising the gaseous mixture originating from step (a) to a separation-enhanced reverse water gas shift reaction; and (c) subjecting the gaseous mixture originating from step (b) to DME/synthesis gas separation to obtain DME and a gaseous mixture comprising synthesis gas, which is recycled to step (a). Herein, the feedstock is introduced in step (a) or step (b) and the molar ratio of H2 to COx in the gaseous mixture which is subjected to step (b) is at least (x+0.8). Also a system for performing the reaction according to the invention is disclosed.Type: GrantFiled: January 12, 2017Date of Patent: September 1, 2020Assignee: NEDERLANDSE ORGANISATIE VOOR TOEGEPAST-NATUURWETENSCHAPPELIJK ONDERZOEK TNOInventors: Franciscus Petrus Felix Van Berkel, Hendricus Adrianus Johannes Van Dijk, Paul Dean Cobden, Willem Gerrit Haije, Jaap Ferdinand Vente
-
Patent number: 10759729Abstract: The present invention provides a class of novel aryl pseudo-C-glycoside compounds that are effective for treating diabetes. Also provided are methods for making such compounds and methods for treating diabetes by administering such compounds to patients who have been diagnosed with diabetes or are at risk of developing diabetes.Type: GrantFiled: November 7, 2016Date of Patent: September 1, 2020Assignee: The Chinese University of Hong KongInventors: Tony Kung Ming Shing, Wai-Lung Ng, Ho Chuen Li, Kit-Man Lau, Clara Bik San Lau
-
Patent number: 10759730Abstract: Provided is an acetic acid production method that enables, in a scrubbing system, efficient separation and obtaining of methyl iodide and an absorbing solvent; restrainment of corrosion of the interior of a distillation column; efficient separation between and recovery of hydrogen iodide and methyl iodide; or sufficient recovery of hydrogen iodide. The acetic acid production method according to the present invention includes a first absorption step and a second absorption step. In the first absorption step, an offgas is brought into contact with a first absorbent to allow the first absorbent to absorb an iodine compound from the offgas, to give a first gas, where the first absorbent includes at least one of C2 or higher alcohols, esters of C3 or higher carboxylic acids, esters between carboxylic acids and C2 or higher alcohols, ethers, ketones, water, and basic aqueous solutions.Type: GrantFiled: July 2, 2018Date of Patent: September 1, 2020Assignee: DAICEL CORPORATIONInventor: Masahiko Shimizu
-
Patent number: 10759731Abstract: There is provided a method for producing a C2-C20 fluorine-containing organic acid with reduced fluorine-free organic compound. A method for producing a C2-C20 fluorine-containing organic acid, the method including contacting a mixture containing a C2-C20 fluorine-containing organic acid and a fluorine-free organic compound with a concentrated sulfuric acid and then separating a C2-C20 fluorine-containing organic acid phase from a concentrated sulfuric acid phase. The contacting is conducted such that an amount of water present in the concentrated sulfuric acid phase is 10% by mass or less, and the C2-C20 fluorine-containing organic acid is obtained in the form of the C2-C20 fluorinated organic acid phase having a reduced content ratio of the fluorine-free organic compound compared with said mixture.Type: GrantFiled: June 9, 2017Date of Patent: September 1, 2020Assignee: DAIKIN INDUSTRIES, LTD.Inventors: Shuuji Itatani, Mihoko Ohashi
-
Patent number: 10759732Abstract: A process for preparing an ester of (meth)acrylic acid or a derivative thereof comprises reacting (meth)acrylic acid or a derivative thereof with glycerol carbonate at a reaction temperature of 10 to 150° C. without a solvent in the presence of at least one enzyme catalyzing the esterification reaction.Type: GrantFiled: August 16, 2018Date of Patent: September 1, 2020Assignee: BASF SEInventors: Mathieu Blanchot, Uwe Meisenburg, Steffen Maurer, Jochen Petzoldt, Tobias Hoefener, Boris Breitscheidel, Andrea Misske, Friederike Fleischhaker, Martin Kaller, Christoph Fleckenstein, Ulrik Stengel, Ritesh Nair
-
Patent number: 10759733Abstract: The present disclosure provides treprostinil derivatives that can act as prodrugs of treprostinil. The treprostinil derivatives can be used to treat any conditions responsive to treatment with treprostinil, including pulmonary hypertension, such as pulmonary arterial hypertension.Type: GrantFiled: September 24, 2019Date of Patent: September 1, 2020Assignee: Corsair Pharma, Inc.Inventors: Xiaoming Zhang, Meenakshi S. Venkatraman, Cyrus K. Becker
-
Patent number: 10759734Abstract: A process of preparing compounds of general formula I, by cuprate coupling of a vinyl cuprate of general formula II with a protected enone of general formula IV to produce a compound of general formula (V) removing the protecting groups of the compound of general formula (V) and purifying the compound of general formula (I) by chromatography; wherein the vinyl cuprate of formula (II) is prepared by reacting a vinyl stannane of formula III with copper halide CuX and alkyllithium R1Li and wherein an excess of the alkyllithium is decomposed before the said coupling reaction.Type: GrantFiled: June 29, 2018Date of Patent: September 1, 2020Assignee: CHINOIN PHARMACEUTICAL AND CHEMICAL WORKS PRIVATE COMPANY LTD.Inventors: Irén Hortobágyi, István Lászlófi, Zsuzsanna Kardos, József Molnár, László Takács, Kornélia Horváth
-
Patent number: 10759735Abstract: Neuroprotective compounds for reducing neurological damage due to cellular stress in an individual are of Formula 1: or an enantiomer, diastereomer, racemic mixture or a pharmaceutically acceptable salt thereof, wherein: Ar=aryl; Y=aryl substituent (ortho, meta, or para) selected from the group consisting of: alkyl, alkyloxy, alkylamino, R5R6N, and halo; X?O, N, or S; R?H, alkyl, aryl, OH, alkyloxy, aryloxy, NH2, alkylamino, R5R6N, or arylamino; R1 and R2=alkylcarbonyl, arylcarbonyl, alkyl, or H, individually; R3=arylCH?CH, alkylCH?CH, alkyl; R4?H, alkyl, or aryl; and R5 and R6=alkyl, individually. Methods of reducing neurological damage due to cellular stress in an individual include administering to the individual during or after the cellular stress a neuroprotective compound of Formula I in a therapeutically effective amount to restore synaptic function during or after the cellular stress.Type: GrantFiled: January 11, 2019Date of Patent: September 1, 2020Assignee: Florida Atlantic University Board of TrusteesInventors: Salvatore D. Lepore, Kenneth Dawson-Scully, Elijah J. St. Germain, Samantha L. Maki, Wesley L. Bollinger, Nadia K. Sial
-
Patent number: 10759736Abstract: The invention relates to a process for the preparation of di- and polyamines of the diphenylmethane series (MDA), in which firstly crude MDA is prepared and is then subjected to a distillation process, wherein the distillation process comprises the following: in a distillation column, separating off a stream containing aniline and water as head product so as to obtain the first product stream as sump product, in said distillation column or in an apparatus arranged downstream of said distillation column, performing a stripping with steam so as to obtain a gaseous stream containing aniline, water and MMDA, partially condensing this gaseous stream containing aniline, water and MMDA so as to obtain a liquid stream containing MMDA and water (and optionally aniline) and a gaseous stream containing aniline and water (and optionally MMDA), drying the liquid stream containing MMDA and water (and optionally aniline) obtained by the partial condensation so as to obtain the second product stream.Type: GrantFiled: October 10, 2019Date of Patent: September 1, 2020Assignee: Covestro Deutschland AGInventors: Stefan Wershofen, Richard Adamson, Georg Pirkl
-
Patent number: 10759737Abstract: Provided is a method for extracting a 1,5-pentanediamine from a solution system containing a 1,5-pentanediamine salt. The method comprises adding to the solution system an insoluble basic substance to form a solution system containing free 1,5-pentanediamine. The provided method has high applicability, is easy to use, and is environmentally-friendly, significantly lowering raw material costs and operating costs for the entire manufacturing process. The method achieves a high recovery rate for pentanediamine, and is more suitable for industrial-scale production.Type: GrantFiled: September 7, 2016Date of Patent: September 1, 2020Assignees: CATHAY BIOTECH INC., CIBT AMERICA INC.Inventors: Xiucai Liu, Bingbing Qin, Chen Yang
-
Patent number: 10759738Abstract: The present invention provides a process for preparation of isoproterenol hydrochloride (1a) comprising catalytic hydrogenation of 3?,4?-dihydroxy-2-(isopropylamino)-acetophenone hydrochloride (5a) in presence of an ion exchange resin, to provide isoproterenol hydrochloride (1a).Type: GrantFiled: January 3, 2018Date of Patent: September 1, 2020Assignee: EMCURE PHARMACEUTICALS LIMITEDInventors: Mukund Keshav Gurjar, Shashikant Gangaram Joshi, Jagannath Tulsiram Jagtap, Sachin Arvind Badhe
-
Patent number: 10759739Abstract: A compound, or a pharmaceutically acceptable salt thereof, having a formula I of: wherein Ar is an arylene or heteroarylene; R1 has a structure of: wherein W is an alkanediyl, alkenediyl, a carbonyl, or a combination thereof; X is —NR5—, wherein R5 is H or an alkyl, or —O—; and Y is optionally-substituted cycloalkyl, optionally-substituted cycloalkyl-substituted alkyl, optionally-substituted heterocycloalkyl, or optionally-substituted heterocycloalkyl-substituted alkyl; each R2 is the same or different and has a structure of: wherein Z is —NR6—, wherein R6 is H or an alkyl, —O—, —S—, or —CH2—; Z1 is (—CH2—)m wherein m is 0 to 5, or an alkenediyl having 2 to 6 carbon atoms; Cy is a 3-8-membered cycloalkyl, heterocycloalkyl, aryl or heteroaryl ring; and each R4 is the same or different and is selected from hydroxy, halogen, substituted or unsubstituted alkoxy, substituted or unsubstituted alkyl, or amino; and c is 0 to 5; and each R3 is the same or different and is selected from hydroxType: GrantFiled: June 7, 2016Date of Patent: September 1, 2020Assignee: University of Pittsburgh—Of the Commonwealth System of Higher EducationInventor: Xiangqun Xie
-
Patent number: 10759740Abstract: The invention provides an antibacterial compound of formula (I) or a salt thereof, as well as an antibacterial compound of formula (II) or a salt thereof, wherein R1, R2, W, X, Y and n have any of the values defined in the specification.Type: GrantFiled: March 24, 2017Date of Patent: September 1, 2020Assignee: Rutgers, The State University of New JerseyInventors: Kathryn Uhrich, Yingyue Zhang, Allison Faig, Michael Chikindas
-
Patent number: 10759741Abstract: A solvent is at least partially separated from a catalyst. The catalyst comprises nickel and a bidentate phosphorus-containing ligand. The method for separation involves distilling a catalyst solution. The ratio of 2-pentenenitrile to 3-pentenenitrile in distillation column bottoms is controlled to reduce the amount of 3-pentenenitrile which is isomerized to form 2-methyl-3-butenenitrile. Isomerization of 3-pentenenitrile to 2-methyl-3-butenenitrile and subsequent isomerization of 2-methyl-3-butenenitrile to 2-methyl-2-butenenitrile, and/or hydrocyanation of 2-methyl-3-butenenitrile to methylglutaronitrile represents a loss in adiponitrile yield in a process for making adiponitrile.Type: GrantFiled: July 16, 2014Date of Patent: September 1, 2020Assignee: INVISTA North America S.a r.l.Inventors: Sudhir N. V. K. Aki, James M. Garner, William J. Tenn, III, Thomas E. Vos
-
Patent number: 10759742Abstract: Process for the preparation of a compound of Formula (I), the process comprising the reaction of a compound of Formula (II) with malononitrile in the presence of a base and a palladium catalyst, Formula (II) wherein X, Y and Z, independently of each other, represent fluoro, chloro or C1-4alkyl; and L is a leaving group; with the proviso that 1 or 2 of X and Y are, independently of each other, fluoro or chloro.Type: GrantFiled: July 20, 2017Date of Patent: September 1, 2020Assignee: Syngenta Participations AGInventors: Martin Zeller, Nicolas Fedou
-
Patent number: 10759743Abstract: Pd(II)-catalyzed g-G(sp3)-H arylation or heteroarylation of primary amines is realized by using 2-hydroxynicotinaldehyde as a catalytic transient directing group. Importantly, the catalyst and the directing group loading can be lowered to 2% and 4% respectively, thus demonstrating high efficiency of this newly designed transient directing group. Heterocyclic aryl iodides are also compatible with this reaction. Furthermore, swift synthesis of 1,2,3,4-tetrahydronaphthyridine derivatives is accomplished using this reaction.Type: GrantFiled: October 19, 2017Date of Patent: September 1, 2020Assignee: THE SCRIPPS RESEARCH INSTITUTEInventor: Jin-Quan Yu
-
Patent number: 10759744Abstract: A process for the production of formaldehyde-stabilised urea is described comprising the steps of: (a) generating a synthesis gas; (b) subjecting the synthesis gas to one or more stages of water-gas shift in one or more water-gas shift reactors to form a shifted gas; (c) cooling the shifted gas to below the dew point and recovering condensate to form a dried shifted gas; (d) recovering carbon dioxide from the dried shifted gas in a carbon dioxide removal unit to form a carbon dioxide-depleted synthesis gas; (e) synthesising methanol from the carbon dioxide-depleted synthesis gas in a methanol synthesis unit and recovering the methanol and a methanol synthesis off-gas; (f) subjecting at least a portion of the recovered methanol to oxidation with air to form formaldehyde in a stabiliser production unit; (g) subjecting the methanol synthesis off-gas to methanation in a methanation reactor containing a methanation catalyst to form an ammonia synthesis gas; (h) synthesising ammonia from the ammonia synthesis gas iType: GrantFiled: March 22, 2018Date of Patent: September 1, 2020Assignee: Johnson Matthey Public Limited CompanyInventors: Sam Barker, Thomas Davison, John David Pach
-
Patent number: 10759745Abstract: Processes and plants for the production of purified urea solution are described. In a described urea production process, urea is produced in a synthesis section without a high pressure stripper and the urea solution is subjected to purification after the recovery section, to give purified urea solution and off-gas. The purification comprises e.g. steam stripping.Type: GrantFiled: November 9, 2018Date of Patent: September 1, 2020Assignee: Stamicarbon B.V.Inventors: Ronny Albert Mathijs Pustjens, Johan Albert Arno Van Den Tillaart
-
Patent number: 10759746Abstract: The present invention relates to a hydrated crystalline form of 2-acrylamido-2-methylpropane sulfonic acid having a 2-theta powder X-ray diffraction diagram comprising peaks at 10.58°, 11.2°, 12.65°, 13.66°, 16.28°, 18.45°, 20°, 20.4°, 22.5°, 25.5°, 25.88°, 26.47°, 28.52°, 30.28°, 30.8°, 34.09°, 38.19°, 40.69°, 41.82°, 43.74°, 46.04° degrees (+/?0.1°). The present invention also relates to a production method for this form of 2-acrylamido-2-methylpropane sulfonic acid and a preparation method for an aqueous solution A of a salt of this form of 2-acrylamido-2-methylpropane sulfonic acid, and the (co)polymer of this form of -acrylamido-2-methylpropane sulfonic acid.Type: GrantFiled: March 19, 2018Date of Patent: September 1, 2020Assignee: S.P.C.M. SAInventors: Cédrick Favero, Johann Kieffer
-
Patent number: 10759747Abstract: The present invention relates to a method of radiochemical synthesis. Novel methods useful in the synthesis of a positron emission tomography (PET) tracer, and novel intermediates useful in said method are provided that have advantages over known methods.Type: GrantFiled: May 2, 2017Date of Patent: September 1, 2020Assignees: GE HEALTHCARE LIMITED, KINGS COLLEGE LONDONInventors: Imtiaz Khan, Graeme McRobbie, Anna Kirjavainen
-
Patent number: 10759748Abstract: A method of preventing or inhibiting L-cystine crystallization is disclosed, using the compounds of formula I: R1a—[O]v-(-A-L-)m-A-[O]v—R1b?? I wherein A, L, R1a, R1b, m, and v are as described herein. The compounds may be prepared as pharmaceutical compositions, and may be used for the prevention and treatment of conditions that are causally related to L-cystine crystallization, such as comprising (but not limited to) kidney stones.Type: GrantFiled: March 20, 2018Date of Patent: September 1, 2020Assignee: New York UniversityInventors: Michael D. Ward, Zina Zhu
-
Patent number: 10759749Abstract: A nobel therapeutic agent for diabetes which can suppress occurrence of side effects such as persistent hypoglycemia is provided. The active ingredient is a derivative of 1,1-diphenylsemicarbazide or 1,1-diphenylthiosemicarbazide. In particular, the active ingredient is a derivative of 1,1-diphenyl-4-cyclohexyl-semicarbazide or 1,1-diphenyl-4-cyclohexyl-thiosemicarbazide exhibiting hypoglycemic action when orally administered.Type: GrantFiled: August 28, 2017Date of Patent: September 1, 2020Assignees: JCR Pharmaceuticals Co., Ltd., National University Corporation Kone University, National University Corporation Chiba UniversityInventors: Susumu Seino, Kenji Sugawara, Ichiro Mori, Akio Matsumoto, Yoshie Reien
-
Patent number: 10759750Abstract: Pharmaceutical compositions of the invention comprise compounds, compositions, methods useful for the treatment of drug addiction, drug withdrawal, and diseases or conditions that involve dysregulation of glutamate homeostasis in its etiology.Type: GrantFiled: April 27, 2017Date of Patent: September 1, 2020Assignee: Temple University—Of The Commonwealth System Of Higher EducationInventors: Magid A. Abou-Gharbia, Benjamin E. Blass, Wayne E. Childers, Mercy Ramanjulu, George C. Morton
-
Patent number: 10759751Abstract: This invention relates to compounds that are agonists of the muscarinic M1 receptor or M1 and M4 receptors and which are useful in the treatment of muscarinic M1 or M1/M4 receptor mediated diseases. Also provided are pharmaceutical compositions containing the compounds and the therapeutic uses of the compounds. Compounds provided are of formula wherein Q4, Q5, R5, p, V, Q1, Q2, X1, X2 and W are defined herein.Type: GrantFiled: March 7, 2019Date of Patent: September 1, 2020Assignee: Heptares Therapeutics LimitedInventors: Giles Albert Brown, Miles Stuart Congreve, Mark Pickworth, Benjamin Gerald Tehan
-
Patent number: 10759752Abstract: The present invention relates to a composition for the modulation of the activity of non-structure proteins and a compound contained therein.Type: GrantFiled: January 30, 2019Date of Patent: September 1, 2020Assignee: Eberhard Karls Universitaet Tuebingen Medizinische FakultaetInventors: Bernhard Hirt, Claus Zeyher, Corinna Gleiser, Lothar Just
-
Patent number: 10759753Abstract: An object of the present invention is to provide a bismaleimide (D-BMI) modified product in which an amino group of dimer diamine (DDA) is maleimidized, which has the good heat resistance, and has the sufficiently enhanced processability, and a method for producing the same. There are provided: <1> A bismaleimide (D-BMI) modified product in which an amino group of dimer diamine is maleimidized, the bismaleimide modified product having the following characteristics: 1) An acid value of the D-BMI modified product is 2 mg-KOH/g or less. 2) In 1H-NMR, when quantitative comparison is performed using an integrated value (A) of a peak corresponding to a proton of a methylene group directly bound to a nitrogen atom of a maleimide group and an integrated value (B) of a peak corresponding to a vinyl proton of a maleimide group, A/B is 1.25 or more and 2.00 or less.Type: GrantFiled: June 18, 2018Date of Patent: September 1, 2020Assignee: UNITIKA LTD.Inventors: Yuki Yamada, Tatsuya Morikita, Takeshi Yoshida, Akira Shigeta, Yoshiaki Echigo
-
Patent number: 10759754Abstract: There are provided compounds of formula (I) in which R2, R2, R3, R4 and Q can represent various different possibilities. These compounds can be useful as anticancer agents as well as anti-inflammatory agents, anti-proliferative agents and/or anti-metastatic agents.Type: GrantFiled: April 10, 2017Date of Patent: September 1, 2020Assignee: 3R VALO, S.E.C.Inventors: Gervais Bérubé, Carlos Reyes-Moreno
-
Patent number: 10759755Abstract: The present invention addresses the problem of providing; a novel bisphenol compound having an indoline skeleton; and a novel aromatic polycarbonate which uses this bisphenol compound as a starting material dihydroxy compound. The above-described problem is able to be solved by an aromatic polycarbonate that contains a repeating unit represented by general formula (2).Type: GrantFiled: December 16, 2016Date of Patent: September 1, 2020Assignee: Honshu Chemical Industry Co., Ltd.Inventors: Shun Mizoguchi, Xuwang Lu
-
Patent number: 10759756Abstract: Disclosed are small molecule antagonists of ?4?7 integrin, and methods of using them to treat a number of specific diseases or conditions.Type: GrantFiled: April 12, 2019Date of Patent: September 1, 2020Assignee: Morphic Therapeutic, Inc.Inventors: Matthew G. Bursavich, Dawn M. Troast, Bryce A. Harrison, Blaise S. Lippa, Bruce N. Rogers, Kyle D. Konze, Aleksey I. Gerasyuto, Tyler Day, Fu-Yang Lin, Kristopher N. Hahn, Mats A. Svensson, Byungchan Kim, Cheng Zhong, Alexey A. Lugovskoy, Brian Sosa
-
Patent number: 10759757Abstract: A method of preparing a crystalline contrast agent for magnetic resonance imaging from a zwitterionic carboxylic pyridyl ligand includes mixing metal ion and the pyridyl ligand and obtaining crystals therefrom. The crystalline contrast agent includes a manganese-organic or gadolinium-organic 3D framework. The crystalline contrast agent is employed in a kit and a pharmaceutically acceptable composition. The method allows for preparing crystalline contrast agents with superior properties with easily available starting materials and with an economic and efficient process. The method allows for preparing crystalline contrast agents with exceptional water-stability and water-solubility, which exhibit high longitudinal relaxivities and with excellent stabilities under physiological conditions and low cytotoxicity. Further provided is a method for in vivo imaging of a subject, in particular a human, comprising administering the crystalline contrast agent to the subject.Type: GrantFiled: September 21, 2016Date of Patent: September 1, 2020Assignees: Macau University of Science and Technology, Southern Medical UniversityInventors: Jinxiang Chen, Jianxin Pang, Shuwen Liu, Li-Ping Bai, Zhi-Hong Jiang
-
Patent number: 10759758Abstract: The present invention relates to crystalline forms of N-{6-(2-Hydroxypropan-2-yl)-2-[2-(methylsulphonyl)ethyl]-2H-indazol-5-yl}-6-(trifluoromethyl)pyridine-2-carboxamide, to processes for their preparation, to pharmaceutical compositions comprising them and to their use in the control of disorders.Type: GrantFiled: April 25, 2017Date of Patent: September 1, 2020Assignee: Bayer Pharma AktiengesellschaftInventors: Tobias Thaler, Johannes Platzek, Nicolas Guimond
-
Patent number: 10759759Abstract: Disclosed are compounds of formula I, II, and III, and pharmaceutically acceptable salts thereof, which are inhibitors of kallikrein. Also provided are pharmaceutical compositions comprising such a compound, and methods involving use of the compounds and compositions in the treatment and prevention of acquired or hereditary angioedema, or other diseases and conditions characterized by aberrant kallikrein activity.Type: GrantFiled: October 27, 2017Date of Patent: September 1, 2020Assignee: BioCryst Pharmaceuticals, inc.Inventors: Pravin L. Kotian, Yarlagadda S. Babu, V. Satish Kumar, Venkat R. Chintareddy, Weihe Zhang, Lakshminarayana Vogeti
-
Patent number: 10759760Abstract: A method for producing a radiofluorinated compound having an aromatic or heteroaromatic ring carrying [18F] fluorine as first substituent, a bonding unit, which can bind to a peptide or peptide mimetic, and a spacer group connected via bond A1 to the bonding unit and via bond A2 to the ring, wherein the bonding unit has second substituent(s) —OH, —CONH, and/or —COOH. The steps include (a) providing a precursor having the ring carrying a substituent Y, bonding unit with the second substituent(s), and spacer group, wherein substituent Y is —N+(R1R2R3), —NO2, —Cl, —Br, —F, or —I, and R1, R2, and R3 are independently C1-C6 alkyl; and (b) reacting the precursor with a [18F] fluoride anion in the presence of an activation salt to the radiofluorinated compound, which has a cation N+(R4R5R6R7) with R4, R5, R6, and R7 being independently C1-C6 alkyl, wherein the substituent Y is replaced by [18F] fluoride.Type: GrantFiled: November 17, 2017Date of Patent: September 1, 2020Assignee: ABX ADVANCED BIOCHEMICAL COMPOUNDS GMBHInventors: René Martin, René Smits, Ronny Hesse, Alexander Hoepping, Marco Müller, Sandra Hübner
-
Patent number: 10759761Abstract: The present invention relates to a process for the preparation of compounds endowed with phosphodiesterase (PDE4) inhibitory activity having formula (I). The invention also relates to the process for the isolation by crystallization of the compound (I) and to its use for the preparation of pharmaceutical compositions for inhalation in combination with suitable carriers or vehicles. The present invention also relates to solvates and crystal forms of a compound of formula (I). The synthesized product is suitable for use in pharmaceutical applications for instance in the treatment of respiratory diseases.Type: GrantFiled: April 23, 2019Date of Patent: September 1, 2020Assignee: CHIESI FARMACEUTICI S.p.A.Inventors: Alessandro Falchi, Emilio Lutero, Emanuele Ferrari, Fausto Pivetti, Rocco Bussolati, Edoardo Mariani, Orsola Vecchi, Erhard Bappert, Caterina Ventrici
-
Patent number: 10759762Abstract: There are described novel compounds of formula I: which R1, R2, R3, R4, R5, R6, R7, R8, R9 and R10 are each as herein defined.Type: GrantFiled: October 9, 2015Date of Patent: September 1, 2020Assignee: HIGH FORCE RESEARCH LIMITEDInventors: Andrew Whiting, Todd Marder
-
Patent number: 10759763Abstract: A method of preparing a 2,6 disubstituted anilines includes, reacting a 2-amino isophthalic acid diester with sufficient Grignard reagent R2CH2MgX to form the corresponding diol product, dehydrating the diol product to the corresponding dialkene; and hydrogenating the diol product to form the corresponding aniline. The 2,6 disubstituted anilines can be used to produce N-Heterocyclic Carbenes (NHCs). The NHCs can find application in various fields such as organic synthesis, catalysis and macromolecular chemistry. Palladium catalysts containing the NHCs are also described.Type: GrantFiled: December 22, 2017Date of Patent: September 1, 2020Assignee: UMICORE AG & CO. KGInventors: Steven P. Nolan, Sebastien Meiries
-
Patent number: 10759764Abstract: Methods for fluorinating organic compounds utilizing a novel organic reagent are described herein. The invention further discloses the utility of this reagent for incorporation of the 18 F isotope into hydroxyl group-containing organic molecules for PET imaging studies. Preparation of the reagents is described along with isolable intermediate structures from reaction of the reagent with a hydroxyl group-containing organic molecule.Type: GrantFiled: October 17, 2014Date of Patent: September 1, 2020Assignee: President and Fellows of Harvard CollegeInventors: Tobias Ritter, Constanze Nicole Neumann
-
Patent number: 10759765Abstract: Provided are a heterocyclic carboxylic acid amide ligand and applications thereof in a copper catalyzed coupling reaction. Specifically, provided are uses of a compound represented by formula (I), definitions of radical groups being described in the specifications. The compound represented by formula (I) can be used as the ligand in the copper catalyzed coupling reaction of the aryl halogeno substitute, and is used or catalyzing the coupling reaction for forming the aryl halogeno substitute having C—N, C—O, C—S and other bonds.Type: GrantFiled: April 14, 2017Date of Patent: September 1, 2020Assignee: CE Pharm Co., Ltd.Inventors: Dawei Ma, Wei Zhou, Mengyang Fan, Haibo Wu, Junli Yin, Xi Jiang, Yuntong Zhai, Songtao Niu
-
Patent number: 10759766Abstract: Chemical entities based on quinoxaline that are kinase inhibitors are described. Specifically, quinoxaline derivatives of Formula I, containing a diarylamide or diarylurea substructure that inhibit Braf mutant kinase activity, pharmaceutical compositions containing the inhibitor compounds and methods of treatment of cancer comprising administering an effective amount of the Braf inhibitor compound are described.Type: GrantFiled: March 20, 2019Date of Patent: September 1, 2020Assignee: NEUPHARMA, INC.Inventors: Xiangping Qian, Yong-Liang Zhu
-
Patent number: 10759767Abstract: The present invention relates to compositions comprising, 1) as component I a compound of formula I, as defined in the claims and description, and 2) as component II an active ingredient, selected from the groups A) to O) defined in the claims and description.Type: GrantFiled: December 18, 2013Date of Patent: September 1, 2020Assignee: BASF AGRO B.V.Inventors: Jan Klaas Lohmann, Egon Haden, Dieter Strobel, Siegfried Strathmann, Martin Semar, Frederik Menges, Nadege Boudet
-
Patent number: 10759768Abstract: The present invention provides a prophylactic or therapeutic agent for an autism spectrum disorder containing compound (I) having melatonin receptor affinity. A compound represented by the formula: wherein each symbol is as described in the specification, or a salt thereof.Type: GrantFiled: January 5, 2017Date of Patent: September 1, 2020Assignee: TAKEDA PHARMACEUTICAL COMPANY LIMITEDInventors: Keisuke Hirai, Takashi Ishikawa
-
Patent number: 10759769Abstract: Described herein are compounds of Formula I, methods of making such compounds, pharmaceutical compositions and medicaments containing such compounds, and methods of using such compounds to treat or prevent diseases or conditions associated with the enzyme glucosylceramide synthase (GCS).Type: GrantFiled: January 18, 2019Date of Patent: September 1, 2020Inventor: Bing Wang
-
Patent number: 10759770Abstract: Compositions and processes for producing high purity acesulfame potassium are described. One process comprises the steps of providing a crude acesulfame potassium composition comprising acesulfame potassium and acetoacetamide, concentrating the crude acesulfame potassium composition to form a water stream and an intermediate acesulfame potassium composition comprising acesulfame potassium and less than 33 wppm acetoacetamide, and separating the intermediate acesulfame potassium composition to form the finished acesulfame potassium composition comprising acesulfame potassium and less than 33 wppm acetoacetamide. The concentrating step is conducted at a temperature below 90° C. and the separating step is conducted at a temperature at or below 35° C.Type: GrantFiled: November 15, 2019Date of Patent: September 1, 2020Assignee: Celanese International CorporationInventors: Christoph Mollenkopf, Peter Groer, Arvind Yadav
-
Patent number: 10759771Abstract: Compositions and processes for producing high purity acesulfame potassium are described. One process comprises the steps of forming a cyclic sulfur trioxide adduct; hydrolyzing the cyclic sulfur trioxide adduct to form an acesulfame-H composition comprising acesulfame-H; neutralizing the acesulfame-H in the acesulfame-H composition to form a crude acesulfame potassium composition comprising acesulfame potassium and less than 2800 wppm acetoacetamide-N-sulfonic acid, wherein the neutralizing step is conducted or maintained at a pH at or below 11.0; and treating the crude acesulfame potassium composition to form the finished acesulfame potassium composition comprising acesulfame potassium and less than 37 wppm acetoacetamide-N-sulfonic acid.Type: GrantFiled: November 15, 2019Date of Patent: September 1, 2020Assignee: Celanese International CorporationInventors: Christoph Mollenkopf, Peter Groer, Arvind Yadav
-
Patent number: 10759772Abstract: The present invention relates to a process For the preparation of Dapagliflozin DL-Proline co-crystal and its use in the preparation/purification of Dapagliflozin. The invention also provides a process for the preparation of Dapagliflozin (R,S)-1.2-propanediol monohydrate.Type: GrantFiled: April 28, 2017Date of Patent: September 1, 2020Assignee: Aurobindo Pharma LtdInventors: Senthilkumar Natrajan, Kishore Karumanchi, Vittal Tangirala, Sivakumaran Meenakshisunderam
-
Patent number: 10759773Abstract: Polycyclocarbonate compounds and upgraded molecular weight polymers made from such compounds are provided. The polymers have particular utility in coating compositions, especially for use on food and beverage contact substrates that are formed into or will be formed into containers or container components.Type: GrantFiled: May 29, 2018Date of Patent: September 1, 2020Assignee: SWIMC LLCInventors: Sebastien Gibanel, Benoit Prouvost
-
Patent number: 10759774Abstract: The present invention provides novel compounds and methods for treating, preventing or inhibiting hepatitis B virus (HBV).Type: GrantFiled: September 27, 2018Date of Patent: September 1, 2020Assignees: THE CURATORS OF THE UNIVERSITY OF MISSOURI, REGENTS OF THE UNIVERSITY OF MINNESOTAInventors: Stefan G. Sarafianos, Zhengqiang Wang, Andrew D. Huber, Jing Tang